CRISM Therapeutics Corporation
Research CRISM Therapeutics Corporation (CRTX) on Bullrun: market cap GBX 851.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRTX
- ExchangeLSE
- CountryBritish Virgin Islands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 851.24M
- Financial periodFY2025
- RevenueGBP 231.00K
- Revenue growth824.0%
- Net income-GBP 1.90M
- Free cash flow-GBP 2.00M
- Gross margin56.7%
Valuation Snapshot
latest market cap is GBX 851.24M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 231.00K | -GBP 1.90M | -GBP 2.00M | 56.7% | -0.05 | GBP 1.13M | n/a | GBP 1.42M |
| FY2024 | GBP 25.00K | -GBP 607.00K | -GBP 961.00K | 84.0% | -0.02 | GBP 1.28M | GBP 0 | GBP 1.48M |
| FY2023 | GBP 45.00K | -GBP 196.00K | -GBP 110.00K | 28.9% | -0.87 | GBP 1.00K | GBP 393.00K | -GBP 601.00K |
| FY2022 | GBP 0 | -GBP 2.49M | -GBP 2.90M | n/a | -0.29 | GBP 2.88M | n/a | GBP 22.99M |
| FY2021 | GBP 0 | -GBP 893.57K | -GBP 1.67M | n/a | -0.15 | GBP 4.95M | n/a | GBP 22.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | GBX 851.24M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CRISM Therapeutics Corporation's market cap?
CRISM Therapeutics Corporation's market capitalization is GBX 851.24M.
What does CRISM Therapeutics Corporation do?
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024.